Shumate Garrett T, Chopra Rajesh, Jones Derek, Messina Darin J, Hee Christopher K
Allergan plc, Irvine, California.
Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California.
Dermatol Surg. 2018 Aug;44(8):1075-1083. doi: 10.1097/DSS.0000000000001525.
An advantage of hyaluronic acid (HA)-based fillers is reversibility.
To evaluate the ability of 2 hyaluronidases to degrade 3 HA-based fillers using a novel in vivo model.
Rats were injected with 3 HA fillers (HYC-24L+, VYC-20L, and RES-L) to create a projecting bolus. After 4 days, recombinant human hyaluronidase (HX) or ovine hyaluronidase (VIT) was administered at (1) varying doses (5 U, 10 U, or 30 U per 0.1 mL filler) or (2) different dilutions (10 U diluted 3-fold). The impact of tissue integration was assessed by administering 10 U/0.1 mL filler 4 weeks after filler injection. Three-dimensional images quantified projection loss over 72 hours.
Complete loss of projection was achieved for all fillers with the highest HX and VIT doses; lower doses achieved less degradation. No difference in degradation was observed between HYC-24L+ and VYC-20L using HX or VIT. RES-L was slightly more degraded with 10 U VIT but not with 10 U HX. Enzyme dilution resulted in less degradation. Tissue integration did not impact the degree of degradation.
This model incorporates the biological system while controlling variables including filler depth and volume and location of hyaluronidase delivery. Hyaluronic acid filler degradation by exogenous hyaluronidase was not hindered by differences among fillers.
基于透明质酸（HA）的填充剂的一个优点是具有可逆性。
使用一种新型体内模型评估两种透明质酸酶降解三种基于HA的填充剂的能力。
给大鼠注射三种HA填充剂（HYC-24L+、VYC-20L和RES-L）以形成突出团块。4天后，以（1）不同剂量（每0.1 mL填充剂5 U、10 U或30 U）或（2）不同稀释度（10 U稀释3倍）给予重组人透明质酸酶（HX）或羊透明质酸酶（VIT）。在填充剂注射4周后给予10 U/0.1 mL填充剂，评估组织整合的影响。通过三维图像量化72小时内的突出物损失。
使用最高剂量的HX和VIT时，所有填充剂的突出物均完全消失；较低剂量的降解程度较小。使用HX或VIT时，HYC-24L+和VYC-20L之间的降解没有差异。使用10 U VIT时RES-L的降解略多，但使用10 U HX时并非如此。酶稀释导致降解减少。组织整合不影响降解程度。
该模型纳入了生物系统，同时控制了包括填充剂深度、体积和透明质酸酶给药位置等变量。外源性透明质酸酶对透明质酸填充剂的降解不受填充剂之间差异的阻碍。
